Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis
Introduction The latest evidence revealed that dupilumab, an interleukin-4 (IL-4) and interleukin-13 (IL-13) blocker, significantly reduces the exacerbation risk in patients with chronic obstructive pulmonary disease (COPD). The efficacy of dupilumab compared with conventional inhaled drugs remains...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2024-05-01
|
| Series: | Archives of Medical Science |
| Subjects: | |
| Online Access: | https://www.archivesofmedicalscience.com/Incremental-long-term-benefit-of-drug-therapies-for-chronic-obstructive-pulmonary,183025,0,2.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584785589960704 |
|---|---|
| author | Qiong Pan Jiongzhou Sun Shiyuan Gao Zian Liu Yiwen Huang Yixin Lian |
| author_facet | Qiong Pan Jiongzhou Sun Shiyuan Gao Zian Liu Yiwen Huang Yixin Lian |
| author_sort | Qiong Pan |
| collection | DOAJ |
| description | Introduction
The latest evidence revealed that dupilumab, an interleukin-4 (IL-4) and interleukin-13 (IL-13) blocker, significantly reduces the exacerbation risk in patients with chronic obstructive pulmonary disease (COPD). The efficacy of dupilumab compared with conventional inhaled drugs remains incompletely determined. This study aimed to investigate the comparative efficacy of dupilumab and conventional inhaled drugs in patients with stable COPD.
Material and methods
This study retrieved randomised clinical trials (RCTs) with follow-up ≥ 48 weeks on long-acting β-agonists (LABAs), long-acting muscarinic receptor antagonists (LAMAs), inhaled corticosteroids (ICSs), and dupilumab in the PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases. The information on eligible studies was extracted after the screening. The comparative efficacy of 4 drugs and their combinations in acute exacerbation and mortality was assessed using Bayesian network meta-analysis models.
Results
This network meta-analysis identified 69 eligible RCTs on 7 classes of drug therapies after stepwise screening and included 125,331 COPD patients. Compared with placebo, the 7 drug interventions significantly reduced the risk of acute exacerbation, and the reduction degree increased with the incremental use of drug classes. ICS/LABA/LAMA/dupilumab was the most effective in decreasing exacerbation risk (OR = 0.561 [95% CI: 0.387–0.810]), followed by ICS/LABA/LAMA (OR = 0.717 [95% CI: 0.626–0.817]). The 7 drug therapies were not significantly associated with a lower risk of death compared to placebo. Nevertheless, ICS/LABA/LAMA/dupilumab is the most likely to be effective in decreasing mortality.
Conclusions
The incremental use of combinations of conventional and novel drugs contributed to the long-term benefits in acute exacerbation but not death in COPD. The optimal drug combination in terms of acute COPD exacerbation was ICS/LABA/LAMA/dupilumab. |
| format | Article |
| id | doaj-art-4e2c3c562e7c452994515980f24b5f6e |
| institution | Kabale University |
| issn | 1734-1922 1896-9151 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Archives of Medical Science |
| spelling | doaj-art-4e2c3c562e7c452994515980f24b5f6e2025-01-27T10:44:31ZengTermedia Publishing HouseArchives of Medical Science1734-19221896-91512024-05-012051586159610.5114/aoms/183025183025Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysisQiong Pan0Jiongzhou Sun1Shiyuan Gao2Zian Liu3Yiwen Huang4Yixin Lian5Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, PR ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, PR ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, PR ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, PR ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, PR ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, PR ChinaIntroduction The latest evidence revealed that dupilumab, an interleukin-4 (IL-4) and interleukin-13 (IL-13) blocker, significantly reduces the exacerbation risk in patients with chronic obstructive pulmonary disease (COPD). The efficacy of dupilumab compared with conventional inhaled drugs remains incompletely determined. This study aimed to investigate the comparative efficacy of dupilumab and conventional inhaled drugs in patients with stable COPD. Material and methods This study retrieved randomised clinical trials (RCTs) with follow-up ≥ 48 weeks on long-acting β-agonists (LABAs), long-acting muscarinic receptor antagonists (LAMAs), inhaled corticosteroids (ICSs), and dupilumab in the PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases. The information on eligible studies was extracted after the screening. The comparative efficacy of 4 drugs and their combinations in acute exacerbation and mortality was assessed using Bayesian network meta-analysis models. Results This network meta-analysis identified 69 eligible RCTs on 7 classes of drug therapies after stepwise screening and included 125,331 COPD patients. Compared with placebo, the 7 drug interventions significantly reduced the risk of acute exacerbation, and the reduction degree increased with the incremental use of drug classes. ICS/LABA/LAMA/dupilumab was the most effective in decreasing exacerbation risk (OR = 0.561 [95% CI: 0.387–0.810]), followed by ICS/LABA/LAMA (OR = 0.717 [95% CI: 0.626–0.817]). The 7 drug therapies were not significantly associated with a lower risk of death compared to placebo. Nevertheless, ICS/LABA/LAMA/dupilumab is the most likely to be effective in decreasing mortality. Conclusions The incremental use of combinations of conventional and novel drugs contributed to the long-term benefits in acute exacerbation but not death in COPD. The optimal drug combination in terms of acute COPD exacerbation was ICS/LABA/LAMA/dupilumab.https://www.archivesofmedicalscience.com/Incremental-long-term-benefit-of-drug-therapies-for-chronic-obstructive-pulmonary,183025,0,2.htmldrug therapychronic obstructive pulmonary diseasemortalityexacerbationnetwork meta-analysis |
| spellingShingle | Qiong Pan Jiongzhou Sun Shiyuan Gao Zian Liu Yiwen Huang Yixin Lian Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis Archives of Medical Science drug therapy chronic obstructive pulmonary disease mortality exacerbation network meta-analysis |
| title | Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis |
| title_full | Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis |
| title_fullStr | Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis |
| title_full_unstemmed | Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis |
| title_short | Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis |
| title_sort | incremental long term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality a network meta analysis |
| topic | drug therapy chronic obstructive pulmonary disease mortality exacerbation network meta-analysis |
| url | https://www.archivesofmedicalscience.com/Incremental-long-term-benefit-of-drug-therapies-for-chronic-obstructive-pulmonary,183025,0,2.html |
| work_keys_str_mv | AT qiongpan incrementallongtermbenefitofdrugtherapiesforchronicobstructivepulmonarydiseaseinqualityoflifebutnotmortalityanetworkmetaanalysis AT jiongzhousun incrementallongtermbenefitofdrugtherapiesforchronicobstructivepulmonarydiseaseinqualityoflifebutnotmortalityanetworkmetaanalysis AT shiyuangao incrementallongtermbenefitofdrugtherapiesforchronicobstructivepulmonarydiseaseinqualityoflifebutnotmortalityanetworkmetaanalysis AT zianliu incrementallongtermbenefitofdrugtherapiesforchronicobstructivepulmonarydiseaseinqualityoflifebutnotmortalityanetworkmetaanalysis AT yiwenhuang incrementallongtermbenefitofdrugtherapiesforchronicobstructivepulmonarydiseaseinqualityoflifebutnotmortalityanetworkmetaanalysis AT yixinlian incrementallongtermbenefitofdrugtherapiesforchronicobstructivepulmonarydiseaseinqualityoflifebutnotmortalityanetworkmetaanalysis |